1. IMS National Sales Perspectives, February 2009.
2. The Joint Commission. Accreditation Program: Hospitals.
Chapter: National Patient Safety Goals.
http://www.jointcommission.org/NR/rdonlyres/31666E86-E7F4-423E-9BE8-F05BD1CB0AA8/0/HAP_NPSG.pdf.
Accessed November 28, 2008.
3. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007
guidelines for the management of patients with unstable angina/non–ST-elevation
myocardial infarction—executive summary: a report of the American College of Cardiology/American
Heart Association Task Force on Practice Guidelines (Writing Committee to Revise
the 2002 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation
Myocardial Infarction): developed in collaboration with the American College of
Emergency Physicians, American College of Physicians, Society of Academic Emergency
Medicine, Society for Cardiovascular Angiography and Interventions, and Society
of Thoracic Surgeons. J Am Coll Cardiol. 2007;50(7):652-726.
4. U.S. Department of Health and Human Services. The Surgeon
General’s call to action to prevent deep vein thrombosis and pulmonary embolism:
2008. Office of the Surgeon General website. http://www.surgeongeneral.gov/topics/deepvein/calltoaction/call-to-action-on-dvt-2008.pdf.
September 15, 2008. Accessed October 20, 2008.
5. Rosamond W, Flegal K, Friday G, et al; American Heart
Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease
and stroke statistics—2007 update: a report from the American Heart Association
Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007;115(5):e69-e171.
6. LOVENOX® (enoxaparin sodium injection) Prescribing Information.
sanofi-aventis, Bridgewater, NJ.
7. Alikhan R, Cohen AT, Combe S, et al. Prevention of venous
thromboembolism in medical patients with enoxaparin: a subgroup analysis of the
MEDENOX study. Blood Coagul Fibrinolysis. 2003;14(4):341-346.
8. IMS In-hospital Sales, October 1995–September 2007.
9. Samama MM, Cohen AT, Darmon J-Y, et al; Prophylaxis in
Medical Patients with Enoxaparin Study Group. A comparison of enoxaparin with placebo
for the prevention of venous thromboembolism in acutely ill medical patients. N
Engl J Med. 1999;341(11):793-800.
10. Data on file, sanofi-aventis, Bridgewater, NJ.
11. Colwell CW Jr, Collis DK, Paulson R, et al. Comparison
of enoxaparin and warfarin for the prevention of venous thromboembolic disease after
total hip arthroplasty: evaluation during hospitalization and three months after
discharge. J Bone Joint Surg Am. 1999;81-A(7):932-940.
12. Fitzgerald RH Jr, Spiro TE, Trowbridge AA, et al; Enoxaparin
Clinical Trial Group. Prevention of venous thromboembolic disease following primary
total knee arthroplasty: a randomized, multicenter, open-label, parallel-group comparison
of enoxaparin and warfarin. J Bone Joint Surg Am. 2001;83-A(6):900-906.
13. Bergqvist D, Benoni G, Björgell O, et al. Low-molecular-weight
heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip
replacement. N Engl J Med. 1996;335(10):696-700.
14. ENOXACAN Study Group. Efficacy and safety of enoxaparin
versus unfractionated heparin for prevention of deep vein thrombosis in elective
cancer surgery: a double-blind randomized multicentre trial with venographic assessment.
Br J Surg. 1997;84(8):1099-1103.
15. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight
heparin administered primarily at home with unfractionated heparin administered
in the hospital for proximal deep-vein thrombosis. N Engl J Med. 1996;334(11):677-681.
16. Merli G, Spiro TE, Olsson C-G, et al; Enoxaparin Clinical
Trial Group. Subcutaneous enoxaparin once or twice daily compared with intravenous
unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern
Med. 2001;134(3):191-202.
17. Antman EM, Morrow DA, McCabe CH, et al; ExTRACT-TIMI
25 Investigators. Enoxaparin versus unfractionated heparin with fibrinolysis for
ST-elevation myocardial infarction. N Engl J Med. 2006;354(14):1477-1488.
18. Antman EM, Morrow DA, McCabe CH, et al; ExTRACT-TIMI
25 Investigators. Enoxaparin versus unfractionated heparin as antithrombin therapy
in patients receiving fibrinolysis for ST-elevation myocardial infarction: design
and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial
Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI
25). Am Heart J. 2005;149(2):217-226.
19. Cohen M, Demers C, Gurfinkel EP, et al; Efficacy and
Safety of Subcutaneous Enoxaparin in Non–Q-Wave Coronary Events Study Group. A comparison
of low-molecular-weight heparin with unfractionated heparin for unstable coronary
artery disease. N Engl J Med. 1997;337(7):447-452.
20. Goodman SG, Cohen M, Bigonzi F, et al; Efficacy and
Safety of Subcutaneous Enoxaparin in Non–Q Wave Coronary (ESSENCE) Study Group.
Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated
heparin for unstable coronary artery disease: one-year results of the ESSENCE study.
J Am Coll Cardiol. 2000;36(3):693-698.
21. Spencer FA, Lessard D, Emery C, Reed G, Goldberg RJ.
Venous thromboembolism in the outpatient setting. Arch Intern Med. 2007;167(14):1471-1475.
22. de Jong JD, Westert GP, Lagoe R, Groenewegen PP. Variation
in hospital length of stay: do physicians adapt their length of stay decisions to
what is usual in the hospital where they work? Health Serv Res. 2006;41(2):374-394.
23. Basse L, Thorbøl JE, Løssl K, Kehlet H. Colonic surgery
with accelerated rehabilitation or conventional care. Dis Colon Rectum.
2004;47(3):271-278.
24. Anderson FA Jr, Hirsh J, White K, Fitzgerald RH Jr.
Temporal trends in prevention of venous thromboembolism following primary total
hip or knee arthroplasty 1996–2001: findings from the hip and knee registry. Chest.
2003;124(6 suppl):349S-356S.
25. Fuster V, Alexander RW, O’Rourke RA, eds. Hurst’s The
Heart. 10th ed. New York, NY: McGraw-Hill Medical Publishing Division;
2001.
26. Lee S, Gibson CM. Enoxaparin in acute coronary syndromes.
Expert Rev Cardiovasc Ther. 2007;5(3):387-399.
27. Weitz JI. Low-molecular-weight heparins. N Engl J Med.
1997;337(10):688-698.
28. Warkentin TE, Roberts RS, Hirsh J, Kelton JG. An improved
definition of immune heparin-induced thrombocytopenia in postoperative orthopedic
patients. Arch Intern Med. 2003;163(20):2518-2524.
29. Le Liboux A, Sanderink G-J, Grosjean P, et al. Enoxaparin
pharmacokinetics and pharmacodynamics after intravenous bolus administration alone
and at initiation of a subcutaneous dosing regimen [abstract 1106-129]. J Am Coll
Cardiol. 2000;35(suppl 1):373A-374A.
30. Martin JL, Fry ETA, Sanderink G-J, et al. Reliable anticoagulation
with enoxaparin in patients undergoing percutaneous coronary intervention: the Pharmacokinetics
of Enoxaparin in PCI (PEPCI) study. Catheter Cardiovasc Interv. 2004;61(2):163-170.
31. Turpie AGG, Levine MN, Hirsh J, et al. A randomized
controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein
thrombosis in patients undergoing elective hip surgery. N Engl J Med. 1986;315(15):925-929.
32. Leclerc JR, , Geerts WH, Desjardins L, et al. Prevention
of deep vein thrombosis after major knee surgery—a randomized, double-blind trial
comparing a low molecular weight heparin fragment (enoxaparin) to placebo. Thromb
Haemost. 1992;67(4):417-423.
33. Goodman SG, Fitchett D, Armstrong PW, Tan M, Langer
A; Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment
(INTERACT) Trial Investigators. Randomized evaluation of the safety and efficacy
of enoxaparin versus unfractionated heparin in high-risk patients with non–ST-segment
elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor
eptifibatide. Circulation. 2003;107(2):238-244.
34. The SYNERGY Trial Investigators. Enoxaparin vs unfractionated
heparin in high-risk patients with non–ST-segment elevation acute coronary syndromes
managed with an intended early invasive strategy; primary results of the SYNERGY
randomized trial. JAMA. 2004;292(1):45-54.
35. Hylek EM, Regan S, Henault LE, et al. Challenges to the
effective use of unfractionated heparin in the hospitalized management of acute
thrombosis. Arch Intern Med. 2003;163(5):621-627.
36. Skinner N, Moran P. Case Management Adherence Guidelines:
Deep vein thrombosis (DVT). http://www.cmsa.org/portals/0/pdf/CMAG_DVT.pdf. Accessed November 28, 2008.
37. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of
venous thromboembolism: American College of Chest Physicians evidence-based clinical
practice guidelines (8th edition). Chest. 2008;133(6 suppl):331S-453S.
38. Gerotziafas GT, Samama MM. Prophylaxis of venous thromboembolism
in medical patients.Curr Opin Pulm Med. 2004;10(5):356-365.
39. Heit JA, Cohen AT, Anderson FA; VTE Impact Assessment Group.
Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism
(VTE) events in the US. Poster 68. Presented at: 47th Annual Meeting and Exposition
of the American Society of Hematology; December 10-13, 2005; Atlanta, GA.
40. Murin S, Romano PS, White RH. Comparison of outcomes
after hospitalization for deep venous thrombosis or pulmonary embolism. Thromb Haemost.
2002;88(3):407-414.
41. Centers for Medicare & Medicaid Services and Agency for Healthcare
Research and Quality. Hospital CAHPS® (HCAHPS®) Fact Sheet. CMS
website. http://www.cms.hhs.gov/HospitalQualityInits/downloads/HospitalHCAHPSFactSheet200512.pdf.
December 1, 2005. Accessed May 14, 2008.
42. Amin A, Stemkowski S, Lin J, Yang G. Thromboprophylaxis
rates in US medical centers: success or failure? J Thromb Haemost.
2007;5(8):1610-1616.
Important Safety Information
WARNING: SPINAL/EPIDURAL HEMATOMAS
When neuraxial anesthesia (epidural/spinal anesthesia) or spinal puncture is employed,
patients anticoagulated or scheduled to be anticoagulated with low-molecular-weight
heparins or heparinoids for prevention of thromboembolic complications are at risk
of developing an epidural or spinal hematoma, which can result in long-term or permanent
paralysis.
The risk of these events is increased by the use of indwelling epidural catheters
for administration of analgesia or by the concomitant use of drugs affecting hemostasis,
such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, or other
anticoagulants. The risk also appears to be increased by traumatic or repeated epidural
or spinal puncture.
Monitor patients for signs and symptoms of neurological impairment. If neurologic
compromise is noted, urgent treatment is necessary.
Consider the potential benefit versus risk before neuraxial intervention in patients
anticoagulated or to be anticoagulated for thromboprophylaxis (see Warnings and Precautions [5.1] and Drug Interactions [7]).
LOVENOX® (enoxaparin sodium injection) cannot be used interchangeably with other
low-molecular-weight heparins or unfractionated heparin (UFH), as they differ in
their manufacturing process, molecular weight distribution, anti-Xa and anti-IIa
activities, units, and dosage.
As with other anticoagulants, use with extreme caution in patients with conditions
that increase the risk of hemorrhage. Dosage adjustment is recommended in patients
with severe renal impairment. Unless otherwise indicated, agents that may affect
hemostasis should be discontinued prior to LOVENOX® therapy. Bleeding can occur
at any site during LOVENOX® therapy. An unexplained fall in hematocrit (HCT)
or blood pressure should lead to a search for a bleeding site. (See
WARNINGS and
PRECAUTIONS.)
In the ST-segment elevation myocardial infarction (STEMI) pivotal trial, the rates
of major hemorrhages (defined as requiring 5 or more units of blood for transfusion,
or 15% drop in HCT or clinically overt bleeding, including intracranial hemorrhage
[ICH]) at 30 days were 2.1% in the LOVENOX® group and 1.4% in the UFH group.
The rates of ICH at 30 days were 0.8% in the LOVENOX® group and 0.7% in the
UFH group. The 30-day rate of the composite endpoint of death, myocardial infarction
(MI), or ICH (a measure of net clinical benefit) was significantly lower in the
LOVENOX® group (10.1%) as compared to the UFH group (12.2%).
Thrombocytopenia can occur with LOVENOX®. In patients with a history of heparin-induced
thrombocytopenia (HIT), LOVENOX® should be used with extreme caution. Thrombocytopenia
of any degree should be monitored closely. If the platelet count falls below 100,000/mm
3,
LOVENOX® should be discontinued. Cases of HIT have been observed in clinical
practice. (See
WARNINGS and
PRECAUTIONS.)
The use of LOVENOX® has not been adequately studied for thromboprophylaxis in
pregnant women with mechanical prosthetic heart valves. (See
WARNINGS and
PRECAUTIONS.)
LOVENOX® is contraindicated in patients with hypersensitivity to enoxaparin
sodium, heparin, or pork products, and in patients with active major bleeding.
For more information, contact your local sanofi-aventis U.S. Representative or call
sanofi-aventis U.S. Medical Information Services at 1-800-633-1610.
Please see full
Prescribing Information including boxed
WARNING.
Prescription LOVENOX® is available in pharmacies.
